Collegium Q2 revenue $188M (+29% YoY); raises 2025 guidance; authorizes $150M buyback

COLLEGIUM PHARMACEUTICAL, INC

2025-Q2 EPS reported $0.44 vs consensus $1.65 ▼ miss (-73.3%)

Record quarterly product revenue $188.0M, up 29% YoY; GAAP EPS $0.34 diluted; adjusted EPS $1.68.
Jornay PM net revenue $32.6M, prescriptions up 23% YoY; full-year Jornay PM guidance raised to $140-145M.
Pain portfolio revenue $155.4M (+7% YoY) with Belbuca $52.6M, Xtampza $52.6M, Nucynta $46.4M.
Raised FY2025 revenue guidance to $745-760M and adjusted EBITDA to $440-455M; cash $222.2M.
Board authorized $150M share repurchase through Dec 2026; completed $25M ASR in July.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.